Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
A Phase IV Study in Drug-Naive Patients With T2DM in China
This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled Phase IV study to assess the efficacy and safety of Dapagliflozin as monotherapy compared with Acarbose in patients with T2DM who were…
- Trial name
- NCT03344341
- Testing
- Dapagliflozin, Acarbose
- Where
- 20 sites in China
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise
The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes…
- Trial name
- NCT01809327
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR
- Where
- 129 sites in United States, Argentina and 11 more
- Volunteers
- 1,186 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
Primary objective of this study is to confirm the efficacy of HOE490 O (glimepiride/metformin) compared with placebo on top of glimepiride in HbA1c change.
- Trial name
- NCT00924573
- Testing
- Metformin, Glimepiride (HOE490)
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010) in comparison to placebo, as an add-on treatment to metformin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GetGoal-M-Asia (NCT01169779)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 35 sites in China, Hong Kong and 2 more
- Volunteers
- 391 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients
This study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK2330672 compared to sitagliptin when administered with metformin for 14 days to subjects with type 2 diabetes…
- Trial name
- NCT02202161
- Testing
- GSK2330672, Sitagliptin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)
This is a study of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-8666 in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01971554
- Testing
- MK-8666
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC
Obesity Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus
An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)
A worldwide study with extension in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight.
- Trial name
- NCT00430742
- Testing
- Taranabant
- Volunteers
- 600 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Diabetes Mellitus, Type 2
ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria
The purpose of the study is to compare the change from baseline in blood pressures (DBP/SBP) to 16-week regimen between Amtrel® and Co-Diovan®. The secondary objectives were listed as the following.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Albuminuria
- Trial name
- NCT01375322
- Testing
- Amlodipine+Benazepril, Valsartan+Hydrochlorothiazide
- Where
- 4 sites in Taiwan
- Volunteers
- 226 people
- Sponsor
- TSH Biopharm Corporation Limited
Type 2 Diabetes
Evaluation of Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects Diabetic Patients.
Mellitus type 2 diabetes (T2MD) is a chronic disease characterized by high glucose plasmatic level due to an alteration of insulin function. Several authors have correlated this altered function to an inositol depletion.
- Trial name
- MYDIAGYM (NCT04745780)
- Testing
- Myo-inositol, D-chiro-inositol, Gymnema sylvestre, Zinc and Alpha-lactalbumin
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Lo.Li.Pharma s.r.l
Type 2 Diabetes
Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)
This observational retrospective study will describe characteristics of patients with type 2 diabetes mellitus (T2DM) who were initiating use or treatment with sodium-glucose co-transporter-2 (SGLT-2) inhibitors and other…
- Trial name
- NCT03694470
- Where
- Russia
- Volunteers
- 10,000 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus
This study is conducted in Asia, Europe and in the United States of America. The aim of this study is to examine patient and physician beliefs regarding insulin therapy and the degree to which patients adhere to their insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01950650
- Testing
- No treatment given, survey
- Where
- 10 sites in United States, China and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
This study is conducted in Europe. Observational study evaluating the body weight progress during the treatment with insulin detemir (Levemir®) in Type 2 patients, previously treated with other basal insulins
- Trial name
- NCT00697450
- Testing
- insulin detemir
- Where
- Czechia
- Volunteers
- 206 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.
This 2 arm study will compare the safety, tolerability and efficacy of aleglitazar and Actos in patients with type 2 diabetes and symptomatic NYHA class II heart failure.
- Trial name
- NCT00461058
- Testing
- Actos, aleglitazar
- Where
- 45 sites in United States, Israel and 4 more
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with…
- Trial name
- SMART (NCT02243176)
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications…
- Trial name
- ELEMENT 5 (NCT02302716)
- Testing
- LY2963016, LANTUS®, Oral Antihyperglycemic Medication
- Where
- 44 sites in United States, India and 5 more
- Volunteers
- 493 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Regulatory Request NIS in Korea
To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting
- Trial name
- NCT03642717
- Testing
- JARDIANCE DUO®
- Where
- 20 sites in South Korea
- Volunteers
- 658 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.
- Trial name
- NCT00846391
- Testing
- MK8245 5 mg (twice a day) b.i.d., MK8245 50 mg b.i.d.
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
- Trial name
- NCT02386982
- Testing
- HMS5552
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hua Medicine Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.